Lexicon Share Spike On Carcinoid Syndrome Phase III Data

Lexicon Pharmaceuticals Inc. is looking forward to filing its first US NDA after announcing positive top-line Phase III data for its lead product, telotristat etiprate, in treating cancer patients with carcinoid syndrome inadequately controlled by the current standard of care. Shares in the firm shot up by 47% to $12.41 on NASDAQ the morning of Aug. 1, 2015 following the news.